# A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

> **NCT06444204** · PHASE1 · COMPLETED · sponsor: **Principia Biopharma, a Sanofi Company** · enrollment: 29 (actual)

## Conditions studied

- Hepatic Function Abnormal
- Healthy Volunteers

## Interventions

- **DRUG:** Rilzabrutinib

## Key facts

- **NCT ID:** NCT06444204
- **Lead sponsor:** Principia Biopharma, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-03-23
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444204, "A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06444204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*